Skip to Main Content

Paper Details

Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment.
Haematologica
26
2018
JAK, JAK1, JAK2, JAK3, STAT, bone marrow mesenchymal stromal cells, bone marrow stromal cells, human, malignant plasma cells, monoculture, myeloma, myeloma cells, patients, rheumatoid arthritis, ruxolitinib, stromal-responsive human myeloma cell lines, tofacitinib, tumor, venetoclax
Author NameAffiliation
Ian D FergusonUniversity of California san francisco
Ian D FergusonHelen Diller Family Comprehensive Cancer Center, University of California san francisco
Margarette C MarianoUniversity of California san francisco
Margarette C MarianoHelen Diller Family Comprehensive Cancer Center, University of California san francisco
Yu-Hsiu LinUniversity of California san francisco
Yu-Hsiu LinHelen Diller Family Comprehensive Cancer Center, University of California san francisco
Yu-Hsiu LinUniversity of California san francisco
Yu-Hsiu LinHelen Diller Family Comprehensive Cancer Center, University of California san francisco
Jack TauntonUniversity of California san francisco
Arun P WiitaUniversity of California san francisco
Arun P WiitaHelen Diller Family Comprehensive Cancer Center, University of California san francisco
Arun P WiitaUniversity of California san francisco
Arun P WiitaHelen Diller Family Comprehensive Cancer Center, University of California san francisco
  • 1 - 13

Datasets